Area Under the Curve

Area Under the Curve (AUC) quantifies the total exposure of the body to a drug over a defined time period. Plotted on a graph of plasma drug concentration vs time, AUC is the area beneath the curve.

AUC is one of the primary endpoints in bioequivalence studies, where two formulations of the same active ingredient are compared. The FDA standard for bioequivalence requires the 90% confidence interval of the test:reference AUC ratio to fall within 80-125%.

For chronic dosing, AUC over a dosing interval (AUC₀-τ) at steady state describes the steady-state exposure pattern. For single-dose pharmacokinetics, AUC₀-∞ describes the total exposure to a single dose.

Why AUC matters clinically:

- Bioequivalence comparisons. When evaluating a generic vs branded product, or when evaluating different routes (e.g., oral vs intramuscular testosterone), AUC equivalence supports clinical interchangeability. - Dose-finding. Therapeutic AUC ranges have been established for some drugs (notably immunosuppressants); dose adjustment is guided by measured AUC. - Drug interaction characterization. CYP3A4 inhibitors that increase AUC of a coadministered drug can produce clinically significant interactions.

For ED medications, AUC differences between sildenafil and tadalafil reflect the substantial half-life and clearance differences. For TRT formulations, AUC is part of the comparison between weekly injectable, daily transdermal, and twice-daily oral preparations.

Compounded products do not have published AUC data comparing them directly to branded products in the way that FDA-approved generics do. The active pharmaceutical ingredient is the same, but bioequivalence in the formal regulatory sense is not established for compounded preparations.